Selinexor

In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, discusses what she would like to see in the future of myleoproliferate neoplasms care and management.

SAN DIEGO — Akriti Jain, MD, highlights presentations from ASH Annual Meeting and Exposition focused on triplet combination therapy for patients with acute myeloid leukemia.

Selinexor maintenance after systemic therapy extended median PFS more than four times longer than placebo for women with advanced or recurrent TP53 wild-type endometrial cancer, according to phase 3 study results.

The FDA granted fast track designation to two oncology therapies.

Patients with multiple myeloma tumors that featured a three-gene signature demonstrated a higher likelihood of achieving a durable and deep response to selinexor, according to study results published in JCO Precision Oncology.

Selinexor prolonged PFS compared with placebo among women with advanced or recurrent endometrial cancer, according to topline data released by the agent’s manufacturer.

Once weekly selinexor, carfilzomib and dexamethasone was highly active and yielded deep responses in patients with heavily pretreated multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.

Once weekly oral selinexor combined with pomalidomide and dexamethasone was well-tolerated in patients with heavily pretreated multiple myeloma, according to data from the multi-arm phase 1b/2 STOMP study presented at the virtual ASCO Annual Meeting.

The FDA approved selinexor as part of a three-agent regimen for adults with multiple myeloma who received at least one prior therapy.

Once-weekly selinexor, bortezomib and dexamethasone improved outcomes compared with twice-weekly bortezomib and dexamethasone for pretreated multiple myeloma, according to results presented during the ASCO20 Virtual Scientific Program.